8-K
filed June 23, 2023, 7:59 PM ET
ticker FBIO
CIK 0001429260
other material
confidence high
sentiment neutral
materiality 0.40
Fortress Biotech stockholders approve 7M share increase in incentive plan and 1M in ESPP
Fortress Biotech, Inc.
- Stockholders re-elected all eight director nominees to hold office until the 2024 annual meeting.
- Ratified KPMG as independent auditor for 2023 with over 99.6% of votes in favor.
- Approved amendment to 2013 Stock Incentive Plan: shares increased by 7M to 23M total, term extended to Dec 31, 2033.
- Approved amendment to 2012 ESPP: shares increased by 1M to 2M total.
- Both plan amendments became effective upon stockholder approval on June 21, 2023.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Fortress Biotech, Inc. shareholders approved Amendment to the Incentive Plan to increase the shares of Common Stock available for issuance under the Incentive Plan by 7,000,000 shares from 16,000,000 to 23,000,000 and extend the term of the plan to December 31, 2033 at the 2023-06-21 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-06-21
Exact text from the filing
Proposal 3 The vote with respect to the approval of an amendment to Fortress’s Incentive Plan was as follows: Total Votes For Total Votes Against Abstentions Broker Non-Votes 62,543,510 3,400,208 114,917 34,919,105
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Fortress Biotech, Inc. shareholders approved Election of eight directors to hold office until the 2024 annual meeting of stockholders or until such director resigns or is removed from office at the 2023-06-21 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-21
Exact text from the filing
Proposal 1 The votes with respect to the election of eight directors to hold office until the 2024 annual meeting of stockholders were as follows: Director Votes For Votes Withheld Broker Non-Votes Lindsay A. Rosenwald, M.D. 65,231,237 827,398 34,919,105 Michael S. Weiss 63,192,696 2,865,939 34,919,105 Eric R. Rowinsky, M.D. 59,716,534 6,342,101 34,919,105 J. Jay Lobell 63,930,573 2,128,062 34,919,105 Jimmie Harvey, Jr., M.D. 65,276,580 782,055 34,919,105 Dov Klein, C.P.A. 60,924,252 5,134,383 34,919,105 Malcolm Hoenlein 60,908,825 5,149,810 34,919,105 Kevin L. Lorenz, J.D. 60,998,382 5,060,253 34,919,105 Lucy Lu, M.D. 64,968,753 1,089,882 34,919,105
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Fortress Biotech, Inc. shareholders approved Amendment to the ESPP to increase the shares of Common Stock available for issuance under the ESPP by 1,000,000 from 1,000,000 to 2,000,000 at the 2023-06-21 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-06-21
Exact text from the filing
Proposal 4 The vote with respect to the approval of an amendment to Fortress’s ESPP was as follows: Total Votes For Total Votes Against Abstentions Broker Non-Votes 63,118,584 2,791,004 149,047 34,919,105
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Fortress Biotech, Inc. shareholders approved Ratification of the appointment of KPMG LLP as Fortress's independent registered public accounting firm for the year ending December 31, 2023 at the 2023-06-21 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-21
Exact text from the filing
Proposal 2 The vote with respect to the ratification of KPMG LLP as Fortress’s independent registered accounting firm for the year ending December 31, 2023 was as follows: Total Votes For Total Votes Against Abstentions 100,561,358 349,645 66,737
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.